ECOG Performance Status in Mesothelioma: How 1 Score Shapes Your Treatment Options

Your ECOG performance status score — a single number from 0 to 4 — is the strongest independent predictor of how long you will survive with mesothelioma and which treatments you can receive. A 2018 study of 93 pleural mesothelioma patients at National Taiwan University Hospital found that patients with an ECOG score of 2 or higher had a hazard ratio of 5.03 for death compared to patients with scores of 0 or 1 [2]. That means a single-point difference on this scale can determine whether you qualify for immunotherapy, surgery, or clinical trials — or whether your options narrow to palliative care alone.

What Is ECOG Performance Status and How Is It Scored?

ECOG performance status is a standardized scale that physicians use to assess how well a cancer patient can carry out daily activities. Developed by the Eastern Cooperative Oncology Group, the scale runs from 0 (fully active, no restrictions) to 4 (completely bedridden). It takes less than a minute for a physician to assign, yet it carries more prognostic weight than any imaging scan or blood test.

The five ECOG grades are:

• ECOG 0: Fully active. Able to carry on all normal activities without restriction
• ECOG 1: Restricted in physically strenuous activity but ambulatory and able to carry out light work (office work, light housework)
• ECOG 2: Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours
• ECOG 3: Capable of only limited self-care. Confined to bed or chair more than 50% of waking hours
• ECOG 4: Completely disabled. Cannot carry out any self-care. Totally confined to bed or chair

For mesothelioma patients, the difference between ECOG 1 and ECOG 2 is not just a number — it is often the dividing line between eligibility for life-extending treatments and restriction to supportive care [7].

"When I sit down with a newly diagnosed mesothelioma patient, one of the first things the oncologist will assess is their ECOG score. That single number shapes the entire treatment conversation — which clinical trials they can enter, whether surgery is on the table, and what kind of chemotherapy or immunotherapy regimen they can tolerate. It is the starting point for everything."

— David Foster, Executive Director of Client Services, Danziger & De Llano

Why Is ECOG the Strongest Predictor of Mesothelioma Survival?

Multiple large-scale studies confirm that ECOG performance status outperforms virtually every other clinical variable in predicting mesothelioma outcomes. A 2018 study at National Taiwan University Hospital analyzed 93 patients with histologically proven pleural mesothelioma and found that ECOG ≥2 carried a hazard ratio of 5.03 (95% CI: 2.69-9.4) — the highest hazard ratio of any variable tested, including age, stage, and histological subtype [2].

A UK study of 202 mesothelioma patients found that ECOG performance status ≥3 was associated with a hazard ratio of 2.86 (95% CI: 1.64-5.00), confirming it as an independent predictor of poor survival alongside non-epithelioid histology and hypoalbuminemia [9].

In 2023, researchers developing the PLACE prognostic model for mesothelioma assigned ECOG PS >2 the highest point value (2 points) of any variable in their scoring system — more than age, platelet count, lymphocyte count, or calcium levels. High-risk patients (score 0 to 3) had significantly shorter survival than low-risk patients (score <0), with a hazard ratio of 3.878 (95% CI: 2.226-6.755) [10].

The TERAVOLT registry, a global study of 1,491 thoracic cancer patients during COVID-19, also identified ECOG-PS as the single strongest determinant of mortality (OR 2.47), outperforming neutrophil count, procalcitonin, and tumor stage [7].

How Does ECOG Score Determine Which Mesothelioma Treatments You Can Receive?

Your ECOG score directly determines your treatment eligibility. Here is how each level maps to available options:

ECOG 0 (Fully Active): Eligible for the full spectrum of treatments. Multimodal therapy combining surgery (pleurectomy-decortication or extrapleural pneumonectomy), chemotherapy, and radiation is an option for patients with resectable disease [12]. First-line immunotherapy with nivolumab plus ipilimumab is available for unresectable disease. All open clinical trials accept ECOG 0.

ECOG 1 (Restricted but Ambulatory): Eligible for most treatments including immunotherapy. The CheckMate 743 trial enrolled patients with ECOG 0 or 1, and demonstrated median overall survival of 18.1 months with nivolumab plus ipilimumab versus 14.1 months with platinum-pemetrexed chemotherapy (HR 0.74, p=0.002) [1]. Two-year survival rates were 41% for immunotherapy versus 27% for chemotherapy. Most clinical trials accept ECOG 0-1.

ECOG 2 (Ambulatory, Unable to Work): A critical threshold. Standard chemotherapy with platinum-pemetrexed remains available. However, most immunotherapy trials exclude ECOG 2 patients. A Memorial Sloan Kettering analysis of 191 unresectable mesothelioma patients confirmed that PS 0-1 versus ≥2 was an independent predictor of both survival and clinical benefit from first-line chemotherapy [3]. Some second-line trials accept ECOG 0-2.

ECOG 3-4 (Limited Self-Care / Bedridden): Treatment options are limited to palliative care — pain management, pleural effusion drainage, and symptom control. These patients are excluded from virtually all clinical trials and are not candidates for systemic therapy [12].

"The families I work with often ask whether anything can be done to improve a patient's performance status before treatment decisions are finalized. The answer is sometimes yes. Draining a large pleural effusion, treating anemia, optimizing nutrition, and managing pain can genuinely shift a patient from ECOG 2 to ECOG 1 — and that one-point improvement can open doors to immunotherapy and clinical trials that were previously closed."

— David Foster, Executive Director of Client Services, Danziger & De Llano

What Are the EORTC and CALGB Prognostic Scoring Systems?

Two validated scoring systems help oncologists predict mesothelioma survival by combining ECOG performance status with other clinical variables. Both have been independently validated across multiple institutions and countries [4].

The EORTC System (European Organisation for Research and Treatment of Cancer) divides patients into two prognostic groups based on five variables: performance status, histological subtype (epithelioid vs. non-epithelioid), gender, white blood cell count, and diagnostic certainty. Patients in the good-prognosis group had a median survival of 19.2 months compared to 9.9 months for the poor-prognosis group in a UK validation study [5].

The CALGB System (Cancer and Leukemia Group B) uses six variables: ECOG performance status, age, hemoglobin level, white blood cell count, chest pain at presentation, and pleural histology. It classifies patients into six prognostic groups ranging from best to worst outlook [5].

A Leicester study of 142 consecutive mesothelioma patients validated both systems. Significant poor prognostic factors in multivariate analysis included non-epithelial cell type, low hemoglobin, leukocytosis, poor performance status, and male sex. Survival curves were successfully stratified by both the EORTC and CALGB prognostic groups, confirming their clinical utility [4].

A contemporary Memorial Sloan Kettering analysis of 191 patients with unresectable mesothelioma treated with pemetrexed-based chemotherapy confirmed that only three variables retained independent prognostic significance: histological subtype, platelet count (above or below 450,000), and performance status [3].

How Does Histological Subtype Affect Mesothelioma Prognosis?

After ECOG performance status, histological subtype is the second most important prognostic factor. The three main subtypes carry dramatically different survival profiles:

Epithelioid mesothelioma accounts for approximately 60-70% of cases and has the best prognosis. A National Cancer Database analysis of 16,267 patients found that epithelioid histology was significantly associated with longer survival, and female patients with epithelioid tumors had an additional survival advantage (HR 0.85) [6]. The 5-year survival rate for epithelioid pleural mesothelioma is approximately 14% [13].

Sarcomatoid mesothelioma is the most aggressive subtype. A UK cohort found a hazard ratio of 2.22 (95% CI: 1.49-3.31) for sarcomatoid histology compared to epithelioid [9]. The 5-year survival rate is approximately 4%. Critically, immunotherapy appears to offer disproportionate benefit for non-epithelioid patients: the CheckMate 743 5-year update showed 12% 5-year survival for non-epithelioid patients on immunotherapy versus just 1% on chemotherapy [1].

Biphasic mesothelioma contains both epithelioid and sarcomatoid elements. Prognosis depends on the ratio of each component, with higher sarcomatoid proportions predicting worse outcomes. The 5-year survival rate is approximately 5% [13].

"Understanding your histological subtype is essential for treatment planning. With immunotherapy now showing a more-than-tenfold survival advantage for non-epithelioid patients at five years compared to chemotherapy, the treatment conversation has changed dramatically. What was once the worst-prognosis subtype now has a genuine treatment option that can extend life."

— David Foster, Executive Director of Client Services, Danziger & De Llano

What Blood Tests and Other Factors Predict Mesothelioma Outcomes?

Beyond ECOG status and histology, several blood-based biomarkers carry independent prognostic value. These are routinely measured at diagnosis and are incorporated into the EORTC and CALGB scoring systems.

Platelet count: Thrombocytosis (elevated platelet count above 450,000) is an independent poor prognostic marker. The Memorial Sloan Kettering analysis confirmed that platelet count was one of only three variables retaining independent significance in multivariate analysis [3].

Albumin: Hypoalbuminemia (low serum albumin) is an independent predictor of poor survival. A UK study of 202 mesothelioma patients found hypoalbuminemia carried a hazard ratio of 2.07 (95% CI: 1.47-2.92) for death [9]. The CALGB system also incorporates hemoglobin as one of its six scoring variables, reflecting the broader role of nutritional and hematologic status in prognosis.

White blood cell count: Leukocytosis (elevated white blood cell count) is associated with worse outcomes across multiple studies and is included in both the EORTC and CALGB scoring systems [4] [5].

Systemic immune-inflammation index (SII): A 2019 study of 97 mesothelioma patients found that the SII — a composite marker incorporating neutrophils, lymphocytes, and platelets — was an independent prognostic factor. Patients with low SII had a median survival of 47.0 months compared to 13.0 months for patients with high SII [7].

Gender: The National Cancer Database analysis of 16,267 patients found that women had significantly better survival than men (adjusted HR 0.81, 95% CI: 0.77-0.85), even after controlling for age, histology, stage, and treatment [6].

Age: Younger age at diagnosis is consistently associated with better survival. The Taiwanese study found that age ≥70 carried a hazard ratio of 2.66 (95% CI: 1.36-5.22) [2].

What Can Mesothelioma Patients Do to Improve Their Prognosis?

While some prognostic factors are fixed (histology, age, gender), others can be influenced by early intervention and proactive care.

Seek treatment at a specialized mesothelioma center. The accuracy of pathological diagnosis, the range of available treatments, and the experience of the surgical team all affect outcomes. Approximately 14% of mesothelioma diagnoses in high-resource countries are incorrect [7], and treatment at a specialized center reduces this risk.

Pursue rehabilitation before treatment decisions are finalized. A University of Maryland study of 54 patients who underwent pleurectomy-decortication for mesothelioma found that preoperative ECOG was the strongest predictor of postoperative outcomes — including ventilator days, chest tube days, and hospital length of stay. The researchers concluded that patients with mesothelioma should receive rehabilitation early after diagnosis [11].

Address treatable conditions that worsen your ECOG score. Large pleural effusions cause shortness of breath and reduce functional capacity. Draining the fluid can immediately improve mobility and daily functioning. Anemia is treatable with transfusions or erythropoietin. Pain management, nutritional support, and physical therapy can all contribute to improved performance status.

Discuss clinical trial eligibility with your oncologist. As of 2026, more than 93 mesothelioma clinical trials are actively recruiting patients worldwide. Most require ECOG 0-1, but some accept ECOG 0-2. An experienced mesothelioma attorney can help you explore your legal options while your medical team optimizes your treatment plan. Contact Danziger & De Llano at (855) 699-5441 for a free consultation.

"Every week I speak with patients who were told they had no options — and then a second opinion at a specialized center, a targeted intervention to improve their performance status, or a newly opened clinical trial changed the picture entirely. The data in this article is not abstract — it is the framework that guides real treatment decisions for real families."

— David Foster, Executive Director of Client Services, Danziger & De Llano

References

1. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743). Lancet. 2021;397(10272):375-386. PMID: 33485464
2. Wu TH, Lee LJ, Yuan CT, Chen TW, Yang JC. Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients. J Formos Med Assoc. 2018;118(1 Pt 2):230-236. PMID: 29709339
3. Billé A, Krug LM, Woo KM, Rusch VW, Zauderer MG. Contemporary analysis of prognostic factors in patients with unresectable malignant pleural mesothelioma. J Thorac Oncol. 2016;11(2):249-255. PMID: 26845118
4. Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA, O'Byrne KJ. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax. 2000;55(9):731-735. PMID: 10950889
5. Steele JPC, Klabatsa A, Fennell DA, et al. Prognostic factors in mesothelioma. Lung Cancer. 2005;49(Suppl 1):S49-S52. PMID: 15894403
6. Van Gerwen M, Alpert N, Wolf A, et al. Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database. Carcinogenesis. 2019;40(4):529-536. PMID: 30649229
7. Carbone M, Adusumilli PS, Alexander HR, et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019;69(5):402-429. PMID: 31283845
8. Skelin M, Matić K, Anić-Matić A, et al. Immunotherapy in mesothelioma — systematic review and meta-analysis. J Chemother. 2025;38(3):290-301. PMID: 40264298
9. Murphy S, Probert G, Anderson J, et al. Malignant mesothelioma, hypoalbuminaemia and the effect of carboplatin/pemetrexed on survival. Clin Oncol. 2013;25(12):713-718. PMID: 24051173
10. Zhang Y, Li N, Li R, Gu Y, Liu X, Zhang S. Predicting survival for patients with mesothelioma: development of the PLACE prognostic model. BMC Cancer. 2023;23(1):698. PMID: 37495975
11. Ho S, Culligan M, Friedberg J, Goloubeva O, Marchese V. Examining the impact of physical function performance in predicting patient outcomes after lung-sparing surgery for malignant pleural mesothelioma. Disabil Rehabil. 2021;44(22):6676-6683. PMID: 34455883
12. National Cancer Institute. Mesothelioma Treatment (PDQ) — Health Professional Version. cancer.gov. Updated 2026.
13. National Cancer Institute. SEER Cancer Statistics Explorer: Mesothelioma. seer.cancer.gov. Accessed 2025.